Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-082440
Filing Date
2025-06-05
Accepted
2025-06-05 16:52:05
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2024_defa14a_proxy_amend.htm DEFA14A 16002
  Complete submission text file 0000950170-25-082440.txt   17023
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41855 | Film No.: 251027834
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)